Quote:

---

The fact that the 700mg dose was so effective ONLY in the increased CCR5 haplotype speaks to the fact that even that doubled dose did not fully saturate all of the CCR5 which were expressed.

---

With leronlimab achieving 100% receptor occupancy in HIV and Covid where CCR5 expression is spread across the body more broadly I guarantee that it achieves 100% receptor occupancy in NASH where inflammation is more localized.

Why leronlimab is more effective with the CCR5 haplotype is because with increased CCR5 expression you will see increased inflammation which will show increased fibrosis over low or moderate CCR5 expression. With a higher baseline there's a greater amount that can be fixed, therefore a greater difference.